BioMedNewsBreaks

TuesdayMar 09, 2021 11:54 am

BioMedNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Reports Q4, FY 2020 Numbers, Business Highlights

DarioHealth (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, has released its financial and business update report for the fourth quarter and full year 2020. The company reports significant progress across all aspects of its long-term strategic operating plan, including securing several accounts in the B2B (“B2B”) channel that are generating revenue and enrolling members and completing financing that provides capital to move forward on growth initiatives. In addition, DRIO’s acquisition of Upright allows the company to expand its digital therapeutics offering to include musculoskeletal. Other highlights included DRIO’s agreement to provide its digital therapeutics solution to eligible…

Continue Reading

TuesdayMar 09, 2021 11:00 am

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Secures FDA Clearance for Next-Gen NeuroCap(TM)

Brain Scientific (OTCQB: BRSF), a neurology focused medical device and software company, today announced its receipt of U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its next-generation NeuroCap(TM) device. NeuroCap is an advanced electroencephalogram (“EEG”) electrode array used to obtain rapid EEGs in routine clinical and research settings where recording of STAT EEGs is desired. “We are constantly working on new products for the EEG market. In the new version of NeuroCap, we added velcro strips for better adhesion. We also expanded the size range by adding an XS (extra small) size,” said Irina Nazarova, marketing director at Brain…

Continue Reading

MondayMar 08, 2021 2:38 pm

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) to Present at Inaugural Emerging Growth Virtual Conference

180 Life Sciences (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it will present at the Inaugural Emerging Growth Virtual Conference, hosted by M Vest LLC and Maxim Group LLC. The conference is slated to take place from 9:00 a.m.-5:00 p.m. ET on March 17 – 19, 2021, and will feature roundtable discussions with C-suite executives moderated by Maxim Research analysts, fireside chats with live Q&A, as well as presentations from hundreds of domestic and international issuers. According to the update, 180…

Continue Reading

MondayMar 08, 2021 1:54 pm

BioMedNewsBreaks – GT Biopharma Inc. (NASDAQ: GTBP) Releases Preclinical Results for Prostate Cancer Treatment

GT Biopharma (NASDAQ: GTBP), a clinical-stage biopharmaceutical company focused on disruptive, target-directed natural killer (“NK”) cell engager immunotherapy technologies, has announced preclinical results for its ROR1 (“ROR1”) TriKE(TM) (“TriKE”) product candidate, which is being evaluated as a prospective therapy for the treatment of prostate cancer. The treatment is based on the fact that tyrosine kinase transmembrane receptor ROR1 has been shown to be overexpressed on certain cancer cells and to play a functional role in influencing the metastatic potential of various solid tumor cancers. Through its TriKE treatment, GT Biopharma targets ROR1 on cancer cells, redirecting NK cells to attack…

Continue Reading

MondayMar 08, 2021 1:46 pm

BioMedNewsBreaks – MustGrow Biologics Corp. (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) Develops First-Ever Effective Treatment for Root-Rot Disease

MustGrow (CSE: MGRO) (OTCQX: MGROF) (FRA: 0C0) has announced that its plant-based biopesticide is 100% effective against root-rot disease. This announcement followed a recent round of laboratory tests, “which were conducted by an independent third-party lab,” an article on MustGrow’s novel accomplishment details. MustGrow, an agriculture biotech company focused on providing natural science-based biological solutions for high-value crops such as fruits and vegetables, becomes the first to develop an effective treatment for this disease. The “patented mustard-derived biopesticide achieved 100% control over Aphanomyces euteiches zoospores (Aphanomyces) within 24 hours and at economic application rates… Aphanomyces is a soil-borne, root-rot disease…

Continue Reading

MondayMar 08, 2021 1:25 pm

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) Opens First-Ever Pneusomnia Clinic, Unveils New Tech to Test for Sleep Apnea at Home

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing including obstructive sleep apnea (“OSA”), has opened the first Pneusomnia clinic, a clinician-owned, integrated medical-dental sleep center. The center will feature the Vivos System through its Medical Integration Division. Located in Del Mar, California, the clinic is owned and operated by local physicians, including Dr. Mimi Guarneri, a cardiologist, founder and president of the Academy of Integrative Health and Medicine; she will lead the center. Vivos created its Medical Integration Division last year with the objective of fostering an environment where medical…

Continue Reading

MondayMar 08, 2021 12:24 pm

BioMedNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces Development of Newly Designed System for Direct-to-Drain Fluid Waste Management

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that its Skyline Medical Division is renewing the development of a new Generation 3 STREAMWAY(R) System for direct-to-drain fluid waste management. According to the update the new device will see no change to its intended use and will not require a separate 501(k) submission with the Food and Drug Administration. In addition, the new design will include key changes to the product that will be smaller, lighter and easier to install with the goal of improving operator reliability, reducing…

Continue Reading

MondayMar 08, 2021 11:16 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Announces Plans to Participate in 33rd Annual ROTH Conference, $10M Registered Direct Offering

AzurRx BioPharma (NASDAQ: AZRX), a company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced that its CEO and Chairman, James Sapirstein, will participate in a panel discussion during the ROTH Conference slated to be held virtually from March 15-17, 2021. According to the update, the panel, “Therapeutics Against SARS-CoV-2 – Viral Variants Will Not Fade Away: A discussion of various developmental therapeutics for SARS-CoV-2 infection,” is scheduled to begin at 12:00 p.m. ET on March 15, 2021. During the panel, Sapirstein will discuss the need for drug therapies to address issues related to COVID-19, including…

Continue Reading

FridayMar 05, 2021 2:03 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc. Offers Hi-Fi Masks, Other Essentials Amid Pandemic

United Medical Equipment (“UME,” “UMEBSNI”) is the distributor of a comprehensive line of COVID-19 products, including high-filtration (“hi-fi”) masks, the most effective in protecting against the pandemic. According to a recent article, the company offers a separate product line dedicated entirely to the needs of patients and health-care providers whose lives and work are impacted by the COVID-19 pandemic. This includes a wide range hi-fi masks as well as other products such as testing kits, sanitizers, gloves, face shields, thermometers and hoods. “Although shortages of PPE have eased somewhat compared to the start of the pandemic, many health care organizations…

Continue Reading

FridayMar 05, 2021 1:52 pm

BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Solution Holds Ability to Bridge the Gap in Neuro Testing

Brain Scientific (OTCQB: BRSF) is focused on modernizing brain diagnostics through cutting-edge technologies. The company’s NeuroCap(TM) offers a cost-effective, disposable solution that has the ability to bridge the gap in access to neurological testing. A recent article discussing this reads, “The NeuroCap has clear advantages to its bulkier EEG counterpart. The bulkier version requires a skilled specialist to administer, comes with metal disks and wires, requires constant cleaning and sterilization, and takes up to 30 minutes to administer, not including prep or cleaning time. With the NeuroCap, clinical personnel can apply the disposable headset in five minutes or less. This…

Continue Reading